Drug Trial Radar · NCT01482962
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Jul 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
271
Actual
Start
Jun 11, 2012
Primary completion
Jun 30, 2015
Study completion Dec 18, 2017
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL). Note: romidepsin was not used as a single-agent comparator outside the United States of America (USA) as supply was not available.
Conditions
- Relapsed Peripheral T-Cell Lymphoma
- Refractory Peripheral T-Cell Lymphoma
Interventions
AlisertibDrug
Alisertib enteric coated tablets
PralatrexateDrug
Pralatrexate IV infusion
GemcitabineDrug
Gemcitabine IV infusion
RomidepsinDrug
Romidepsin IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) Based on Independent Review Committee (IRC) AssessmentTime frame: Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
- Progression-Free Survival (PFS) Based on IRC AssessmentTime frame: Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years
Locations
151 sites in 31 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
La Jolla, California
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Indianapolis, Indiana
Site not named
Iowa City, Iowa
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
Rochester, Minnesota
Site not named
Jefferson City, Missouri
Site not named
St Louis, Missouri
Site not named
Lebanon, New Hampshire
Site not named
Hackensack, New Jersey
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
Syracuse, New York
Site not named
Durham, North Carolina
Site not named
Columbus, Ohio
Site not named
Toledo, Ohio
Site not named
Charleston, South Carolina
Site not named
Houston, Texas
Site not named
Burlington, Vermont
Site not named
Seattle, Washington
Site not named
Morgantown, West Virginia
Site not named
Adelaide, Australia
Site not named
Concord, Australia
Site not named
Gosford, Australia
Site not named
Hobart, Australia
Site not named
St Leonards, Australia
Site not named
Graz, Austria
Site not named
Innsbruck, Austria
Site not named
Salzburg, Austria
Site not named
Vienna, Austria
Site not named
Minsk Didtrict, Belarus
Site not named
Vitebsk, Belarus
Site not named
Bruges, Belgium
Site not named
Brussels, Belgium
Site not named
Ghent, Belgium
Site not named
Kortrijk, Belgium
Site not named
Turnhout, Belgium
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.